Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.84) by ($0.16), MarketWatch Earnings reports. Alnylam Pharmaceuticals had a negative net margin of 101.01% and a negative return on equity of 109.21%. The company had revenue of $186.90 million for the quarter, compared to analyst estimates of $242.82 million. During the same period in the previous year, the firm posted ($1.71) earnings per share. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year.
Shares of Alnylam Pharmaceuticals stock traded down $9.73 on Friday, hitting $133.43. 1,428,580 shares of the company’s stock traded hands, compared to its average volume of 804,370. The firm’s 50-day moving average price is $160.27 and its two-hundred day moving average price is $166.57. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.04 and a quick ratio of 3.91. The stock has a market capitalization of $16.11 billion, a PE ratio of -17.81 and a beta of 0.85. Alnylam Pharmaceuticals has a one year low of $125.00 and a one year high of $212.00.
In related news, Director Steven M. Paul sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, April 1st. The stock was sold at an average price of $170.69, for a total transaction of $2,560,350.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at $170,690. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.40% of the stock is owned by company insiders.
Several analysts recently commented on ALNY shares. Piper Sandler raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $181.00 to $208.00 in a research note on Monday, January 3rd. Stifel Nicolaus restated a “buy” rating and issued a $215.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, March 24th. StockNews.com started coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, March 31st. They set a “hold” rating for the company. HC Wainwright boosted their price target on shares of Alnylam Pharmaceuticals from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Tuesday, April 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $200.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, February 11th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $218.00.
About Alnylam Pharmaceuticals (Get Rating)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.